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Background and Purpose Three network laboratories measured antibodies to islet
autoantigens. Antibodies to glutamic acid decarboxylase (GAD65 [GADA]) and the
intracellular portion of protein tyrosine phosphatase (IA-2ic [IA-2A]) were measured
by similar, but not identical, methods in samples from participants in the Type 1
Diabetes Genetics Consortium (T1DGC).
Methods All laboratories used radiobinding assays to detect antibodies to in vitro
transcribed and translated antigen, but with different local standards, calibrated
against the World Health Organization (WHO) reference reagent. Using a common
method to calculate WHO units/mL, we compared results reported on samples
included in the Diabetes Autoantibody Standardization Program (DASP), and
developed standard methods for reporting in WHO units/mL. We evaluated intra-
assay and inter-assay coefficient of variation (CV) in blind duplicate samples and
assay comparability in four DASP workshops.
Results Values were linearly related in the three laboratories for both GADA and IA-
2A, and intra-assay technical errors for values within the standard curve were below
13% for GADA and below 8.5% for IA-2A. Correlations in samples tested 1–2 years
apart were >97%. Over the course of the study, internal CVs were 10–20% with
one exception, and the laboratories concordantly called samples GADA or IA-2A
positive or negative in 96.7% and 99.6% of duplicates within the standard curve.
Despite acceptable CVs and general concordance in ranking samples, the
laboratories differed markedly in absolute values for GADA and IA-2A reported in
WHO units/mL in DASP over a large range of values.
Limitations With three laboratories using different assay methods (including
calibrators), consistent values among them could not be attained.
Conclusions Modifications in the assays are needed to improve comparability of
results expressed as WHO units/mL across laboratories. It will be essential to retain
high intra- and inter-assay precision, sensitivity and specificity and to confirm
the accuracy of harmonized methods. Clinical Trials 2010; 7: S56–S64. http://
ctj.sagepub.com
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CV Coefficient of variation
DASP Diabetes Autoantibody
Standardization Program
GADA Glutamic acid decarboxylase
IA-2A Intracellular portion of protein
tyrosine phosphatase
ROC Receiver operating characteristic
SD Standard deviation
T1DGC Type 1 Diabetes Genetics
Consortium
WHO World Health Organization
Introduction
The Type 1 Diabetes Genetics Consortium (T1DGC)
comprises groups of investigators from many
countries throughout the world, with a common
goal of identifying genes predisposing to type 1
diabetes mellitus. Three T1DGC network laborato-
ries (in Asia-Pacific, Europe, and North America)
were selected to measure antibodies to the islet
autoantigens: glutamic acid decarboxylase (GAD65
[GADA]) and the intracellular portion of protein
tyrosine phosphatase (IA-2ic [IA-2A]) as part of the
determination of phenotypes for the project [1–5].
Autoantibodies were measured in samples from all
T1DGC participants with type 1 diabetes. Although
the measurement was not used as an entry criterion
for participation in the study, the research value of
quantifying results in standardized World Health
Organization (WHO) units/mL to allow more
detailed phenotyping became apparent during the
early stages of planning; i.e., that continuous values
would permit additional analysis in relating geno-
types to phenotypes.
This article describes the methods used in these
laboratories, and the quality control procedures to
maintain and monitor the performance of each
laboratory. A masked split duplicate program
allowed assessment of intra- and inter-assay repro-
ducibility over time for each of the assays, includ-
ing assessment of different methods of computing
results reported in WHO units/mL for sera yielding
signals above the highest WHO standard. The
results of the Diabetes Autoantibody Standardiza-
tion Program (DASP) for the three laboratories are
also presented. The DASP workshops aim to
improve and standardize measurement of autoan-
tibodies associated with type 1 diabetes among the
laboratories, and performance in DASP was used as
a criterion for selecting the laboratories and for
monitoring their performance [6,7]. Finally, we
summarize the decisions taken regarding the assay
procedures and reporting of results to bring the
laboratories into closer alignment.
Methods
Given the international nature of the T1DGC and
the extended distances that it covered, there was a
clear need to establish regional laboratories, and
three laboratories were selected on the basis of
performance in DASP, a program organized by the
Immunology of Diabetes Society and the Centers
for Disease Control and Prevention. These labora-
tories have interacted for years (through DASP and
other programs), using radiobinding assays with a
generally similar format [8–10], but some differ-
ences as shown in Table 1. The following sections
summarize the main similarities and differences.
Standards
Each laboratory had prepared local standards cali-
brated to the WHO international reference reagent
for GADA and IA-2A antibodies [11] used over the
course of the DASP workshops [6]. The Asia-Pacific
laboratory collected a serum sample from a patient
with Stiff Person Syndrome (who was highly pos-
itive for both GADA and IA-2A); the European
laboratory used sera from islet cell antibody-
positive relatives of patients with type 1 diabetes;
and the North American laboratory pooled sera
from type 1 diabetes patients and GADA/IA-2A
positive relatives.
Labeled clones
All laboratories used similar clones to prepare target
antigens for both antibodies. For the GADA anti-
body assay, both the Asia-Pacific and European
laboratories used a clone from the same source
(Ezio Bonifacio, Milan, Italy), while the North
American laboratory used a different clone (A ˚ke
Lernmark, Seattle, WA, USA). For the IA-2A anti-
body assay, the Asia-Pacific and North American
labs used a clone from the same source (Ezio
Bonifacio, Milan, Italy), while the European labo-
ratory used a different clone (Michael Christie,
London, UK). All laboratories used similar tran-
scription/translation kits (Promega, Madison, WI,
USA) to produce labeled GADA and IA-2A, followed
by removal of unincorporated label using gel
exclusion chromatography. The Asia-Pacific and
European laboratories labeled both the GADA and
IA-2A proteins with
35S-methionine. The North
American laboratory labeled the IA-2A protein with
35S-methionine and the GADA protein with
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in a single, combined assay.
The similarity of labeling methods used would
be expected to result in the production of qualita-
tively similar labeled proteins for each assay among
the laboratories. There may, however, be consider-
able differences in amounts of proteins actually
present in the labeled material, both within a single
laboratory over several different labeling processes
and between laboratories, as a result of differences
in the specific activities of the labeled proteins
produced and the duration of storage. Indeed, the
amounts of sera and label used varied among the
laboratories (Table 1).
Separation
The laboratories adopted similar, but not identical,
procedures to remove the unbound labeled protein
using protein-A sepharose to bind to the antibody–
antigen complex. The Asia-Pacific and North
American laboratories formed immunocomplexes
in wells in filter plates; to remove any unbound
labeled protein, washes were added to the plate and
removed by vacuum filtration. The North American
laboratory performed two sets of four washes, with
a 5min shake between each set, while the Asia-
Pacific laboratory performed 10 washes. Both lab-
oratories counted the filter plates. The European
laboratory formed immunocomplexes in wells in
deep-well plates and removed the unbound labeled
protein by five cycles of wash, centrifugation, and
aspiration, and transferred the pellets to another
plate for counting in a TopCount b-counter (Perkin
Elmer Life and Analytical Sciences Inc, Waltham,
MA, USA).
Standard curves and interpolation of values
From the start of the project, the laboratories
agreed to calculate results in WHO units/mL
derived from a 7-point standard curve, used each
time an assay was performed. Values above the
highest standard were calculated in two ways:
(a) as an index related to the highest standard:
WHO Units/mL ¼ (value of highest standard)  
[(cpm(unknown) – cpm(negative diluent
serum))/(cpm(WHO standard) – cpm(negative
diluent serum))]
(b) as WHO units/mL derived by extrapolation of
the standard curve.
The European and North American laboratories
used a logarithmic curve fit for calculating values
(Excel, Microsoft), while the Asia-Pacific laboratory
used a spline curve fitting program (Multicalc,
Packard). These programs caused some differences
between laboratories, particularly for extrapolated
values above the range of the standard curve (data
not shown).
Table 1 Comparison of characteristics of the assays in the T1DGC laboratories
Asia-Pacific European North American
Assay format Radiobinding assay in 96-well
filtration plate
Radiobinding assay in 96
deep-well plate
Radiobinding assay in 96-well
filtration plate
Buffer 5mmol/L Tris, 150mmol/L
NaCl, 1mmol/L L-methio-
nine, 0.1% (w/v) BSA, 1%
(v/v) Tween 20, pH 7.4
50mmol/L Tris, 150mmol/L
NaCl, 1% (v/v) Tween 20,
pH 7.4
20mmol/L Tris, 150mmol/L
NaCl, 0.1% (w/v) BSA,
0.1% sodium azide, 0.15%
(v/v) Tween 20, pH 7.4
GADA plasmid Full length Full length Full length (PEX9)
E. Bonifacio E. Bonifacio A. Lernmark
IA-2A plasmid 604–979 606–979 604–979
E. Bonifacio M. Christie E. Bonifacio
Radiolabel
35S-methionine (GADA and IA-
2A)
35S-methionine (GADA and IA-
2A)
3H-leucine (GADA), 35-S
methionine (IA-2A)
30,000 cpm/well in 50mL 15,000 cpm/well in 25mL 20,000 cpm/well in 50mL
Buffer 5mmol/L Tris, 150mmol/L
NaCl, 1mmol/L L-methio-
nine, 0.1% (w/v) BSA, 1%
(v/v) Tween 20, pH 7.4
50mmol/L Tris, 150mmol/L
NaCl, 1% (v/v) Tween 20,
pH 7.4
20mmol/L Tris, 150mmol/L
NaCl, 0.1% (w/v) BSA,
0.1% sodium azide, 0.15%
(v/v) Tween 20, pH 7.4
Primary
incubation
5mL serum in duplicate, 16h
at 4 C
2mL serum in duplicate, 20h
at 4 C
2mL serum in duplicate, 20h
at 4 C
Separation
and washing
5mL/well PAS in 50mL incu-
bated for 1h, washed by
vacuum filtration
5mL/well PAS in 50mL incu-
bated 1.5h, washed by
centrifugation/aspiration
12.5mL/well PAS in 25mL
incubated 0.75h, washed
by vacuum filtration
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Each laboratory defined its own threshold for
calling samples positive or negative for the purposes
of the study. The threshold for the European
laboratory was set as the 97.5th percentile of 2860
schoolchildren expressed in WHO units/mL [9]. The
North American laboratory cut-points were set at
indices of 0.032 for GADA autoantibodies and 0.049
for IA-2A autoantibodies, the 99th percentiles of
198 normal controls including children and adults
who did not have a first degree relative with
diabetes. In Asia-Pacific, the GADA threshold was
determined using a receiver operating characteristic
(ROC) plot of 246 controls and 137 newly diagnosed
patients, with results expressed in local units. The
IA-2A threshold was determined using a ROC plot of
145 controls and 49 newly diagnosed patients, in
local units. These local laboratory units were used to
determine if a sample was positive or negative, but
the results were reported in WHO units.
Quality control procedures
To assess the quality of the measures from the
autoantibody laboratories, a two-pronged system
was implemented. First, univariate analyses were
conducted on the monthly data results uploaded to
the Coordinating Center. Within each laboratory,
results over time were recorded. Based on these
analyses, summary statistics (e.g., means, variances)
and out-of-range values were obtained and, if
necessary, investigated further. Second, duplicate
autoantibody measures were performed on a
random sample of approximately 5% of participants
with type 1 diabetes. Duplicate sera were collected
and labeled with a separate, unique identifier by the
clinic staff and were sent to the laboratories in the
normal sample shipments. The laboratories were
masked as to which samples were paired. These
samples were often measured in the same assay and
are therefore primarily representative of intra-assay
variation. Inter-assay variation was evaluated by a
second split duplicate protocol in which previously
measured duplicate pairs were resubmitted to each
laboratory. The time interval between the initial
and second measurements was 1–2 years.
In addition to graphical inspection of the data,
reliability was assessed using intraclass correlations
and the technical error measurement for autoanti-
body measures. The technical error is the square
root of the pooled between measures variance as a
percentage of the sample mean: ((Sqrt( d
2/2n))/
sample mean)   100). The technical error was
compared to the laboratory’s internal coefficient of
variation (CV). If there was evidence of high
technical error, the laboratory was contacted and
asked for an explanation.
The results of the split duplicates were expressed
as antibody positive or negative (as defined within
each laboratory) and as WHO units/mL determined
both from the standard curves over all values and,
when the values were above the highest standard,
as an index of the highest value.
Results
Intra-assay reproducibility
GADA
The technical errors for the Asia-Pacific, European,
and North American laboratories were 11.2%,
8.8%, and 12.6%, respectively. The internal CV at
low GADA levels were 44.0%, 16.0%, and 18.1%,
respectively, and at high levels were 33.0%, 10.0%,
and 10.8%. By July 4, 2009, a total of 571 intra-
assay split pairs had been tested for GADA: 490 with
values in the range of the standard curve and 81
with values above the highest standard. Within the
standard curve, the mean difference between the
pairs was  0.6 WHO units/mL (standard deviation
[SD] 15.1), with 96.7% concordance in positive/
negative calls within the pairs. For samples with
antibody levels above the highest standard, the
mean difference was  31.4 WHO units/mL (SD
241.4), with 100% concordance in positive/nega-
tive calls within the pairs.
IA-2A
The technical errors for the Asia-Pacific, European,
and North American laboratories were 8.5%, 3.4%,
and 6.0%, respectively. The internal CVs at low IA-
2A levels were 30.0%, 19.0%, and 17.0%, respec-
tively, and at high levels were 30.0%, 20.0%, and
6.7%. By July 4, 2009, a total of 572 intra-assay split
pairs had been tested for IA-2A: 479 with values
within the range of the standard curve and 93 with
values above the highest standard. Within the
standard curve, the mean difference between the
pairs was  0.04 WHO units/mL (SD 7.9), with
99.6% concordance in positive/negative calls
within the pairs. For samples with antibody levels
above the top standard, the mean difference was
 17.6 WHO units/mL (SD 89.7), with 100% con-
cordance in positive/negative calls within the pairs.
Inter-assay reproducibility
Many samples (n¼384) previously assayed as
part of the intra-assay protocol were reassayed
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ity (Figures 1 and 2). Within each laboratory, the
assays demonstrated excellent reproducibility, even
over this time interval.
DASP proficiency evaluations
All three T1DGC laboratories participated in the
four DASP proficiency evaluations conducted since
2000, and during this period achieved levels of
sensitivity and specificity, among the best of the
participating laboratories (Figure 3) as well as good
discrimination between health and disease over
time as assessed by ROC curve analysis.
The results of GADA and IA-2A determinations
in the fourth DASP proficiency workshop [7] with
results expressed in WHO units/mL showed that all
three laboratories assigned the same GADA posi-
tive/negative status in 43 of 50 samples from
patients with newly diagnosed diabetes and 97 of
100 samples from blood donor controls. All three
laboratories assigned the same IA-2A positive/neg-
ative status in 48 of 50 samples from patients and in
93 of 100 samples from controls. The largest IA-2A
discrepancy was in control samples reported as
positive that had very low levels of antibody.
Antibody levels correlated among laboratories
(p<0.0001 for all comparisons). Among the cases,
the correlation coefficients () for GADA antibodies
were 0.727 (Asia-Pacific vs. North American), 0.744
(European vs. North American), and 0.821
(European vs. Asia-Pacific). For IA-2A antibodies,
the correlation coefficients were 0.693 (Asia-Pacific
vs. North American), 0.763 (European vs. North
American), and 0.687 (European vs. Asia-Pacific).
However, as shown in Figure 4(a), the 2005 DASP
evaluation demonstrated systematic differences in
GADA among the laboratories with lowest GADA
antibody levels reported by the North American
laboratory (p<0.0001). In contrast, Figure 4(b)
shows that the Asia-Pacific laboratory reported the
lowest IA-2A levels (p¼0.009).
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Figure 1 GADA inter-assay comparisons of blind duplicates among the T1DGC autoantibody laboratories. Mean values of the
original and repeat assays are plotted. Results above the highest standard have been extrapolated from the standard curve.
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To accomplish a genetics study with a very large
number of participants across continents using
three different laboratories, the T1DGC set quality
control standards for the autoantibody assays to
bring the results into the best possible concordance.
As part of that process, the T1DGC Study Group
reviewed the contemporary protocols and requested
efforts to produce similar results for units of islet
autoantibody level, requiring the laboratories to
examine and contrast their procedures. This com-
munication has summarized the successes and the
challenges of the first efforts to achieve those goals.
An initial change was in the use of the IA-2A
clone that was considered to be likely to be an
important factor in the differences among labora-
tories. An essential part of this process was active
participation of the staff in the laboratories in an
iterative exercise in reviewing and harmonizing
procedures to achieve much greater concordance
among the laboratories.
Ideally, assays are accurate, highly precise,
achieve high specificity and sensitivity, and use
values that can be reported in standard units that
are identical among laboratories and correlate
throughout the range of values found in samples.
Achieving all of these goals is daunting for any
assay, and particularly for islet autoantibody assays
in which one is measuring a mixture of different
molecules of differing affinity and capacity for islet
cell components. Probably no two serum samples
(even from the same individual) have identical
characteristics and, furthermore, no ‘gold standard’
is available. In this study, we evaluated intra-assay
precision, using masked sera, with a split duplicate
program and compared quantitative autoantibody
units across three laboratories using two different
methods for calculating autoantibody levels. With
more than 530 masked duplicate samples (sent
directly from the clinics, mixed with other samples)
assayed concurrently for both GADA and IA-2A, the
intra-assay percentage concordance of original
positive/negative calls in the three laboratories
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Figure 2 IA-2A inter-assay comparisons of blind duplicates among the T1DGC autoantibody laboratories. Mean values of the
original and repeat assays are plotted. Results above the highest standard have been extrapolated from the standard curve.
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excellent correlations overall: R¼0.96 for GADA
and R¼0.99 for IA-2A. Inter-assay variation was not
initially assessed, but the later exercise demon-
strated good inter-assay reproducibility for these
challenging assays over more than 1 year. Accuracy
was also not directly assessed given the lack of an
independent ‘gold standard method’ to determine
actual concentrations of autoantibodies in the sera.
We compared two methods of calculating anti-
body levels above the highest standard: (1) using an
index related to the highest standard and (2)
deriving units by extrapolation of the standard
curve. Our analysis showed that the mean differ-
ence between the pairs was less using the index,
indicating that indexes are more reliable for com-
paring values above the range of the standard
curves, at least with these assays.
Within the structure of the DASP proficiency
evaluations [6], in which 150 masked samples (50
new onset diabetics mixed with 100 healthy con-
trols) have been tested by all laboratories, we were
able to examine differences in assignment of pos-
itive/negative status and in quantification of anti-
body levels using laboratory-defined cutoffs. We
found high levels of concordance in positive/
negative calls among laboratories, with differences
generally occurring only in samples with antibody
levels around the threshold. Over the four DASP
workshops, each of the laboratories called as many
as 7% of controls positive with either the GADA or
IA-2A assays at least once, while other laboratories
with similar sensitivity reported those samples as
negative (Figure 3). Maintenance of specificity
along with sensitivity of the assay is obviously
crucial as efforts are undertaken to harmonize
assays.
A common standard serum sample with defined
WHO units/mL (the WHO reference reagent for
GADA and IA-2A, 97/550 [11]) was circulated in the
DASP workshops and used to calibrate local stan-
dards, permitting levels of these autoantibodies in
four sets of 150 masked serum samples to be
compared among the three T1DGC laboratories.
The rankings of samples according to antibody
levels were similar among the T1DGC laboratories,
but there were systematic differences in the
reported antibody levels for both GADA and IA-2A
(Figure 4(a) and (b)). Thus, in DASP 2005, using the
median results of all participating laboratories as
the method of comparison, the North American
laboratory reported lower GADA levels in cases
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to adjust the North American values to align results
with those of the other laboratories. Similarly, the
lower IA-2A levels reported by the Asia-Pacific
laboratory would need adjustment to yield results
similar to those reported by the European and
North American laboratories. The reasons for the
differences have not been fully elucidated, but the
laboratories have plans to review and carefully
change reagents and protocols within the assays to
harmonize the results. Although not proven, the
most likely explanations for these differences lie in
the different sera used to produce calibrators
utilized in each laboratory and in differences in
the protocols/materials used (Table 1). In particu-
lar, for the GADA assay, the North American
laboratory used
3H-labeled GADA, while both
Asia-Pacific and European laboratories used
35S-labeled GADA. For IA-2A, all laboratories used
35S-methionine labeling.
There are several caveats for the current study. In
particular, we had frequent evaluations of intra-
assay variation but only a single inter-assay assess-
ment of technical error. The lack of a common set
of standards among the laboratories to minimize
long-term drift was a significant impediment to
demonstrating long-term consistency among the
laboratories. Thus, there is a strong need for a true
‘gold standard’ for all human polyclonal autoanti-
body assays. Each laboratory had its own program
to assess long-term drift, but there were no
common T1DGC quality assurance sera to allow
this to be externally evaluated.
Leadership in clinical trials and other research
studies needs to seek ways to improve the perfor-
mance of the laboratories producing results.
Optimally, a single laboratory performing all anal-
yses should yield consistent results among all
samples (assuming the performance of the labora-
tory remained consistent over time) and could
obviate the need to complete the complex compar-
isons among the laboratories presented in this
article. Because the size and complexity of the
T1DGC led to the use of separate laboratories on
three continents in order to complete the work in a
timely manner, we first elected to characterize
results as positive/negative, capitalizing on the
success of DASP over several years. The T1DGC
then initiated quality control measures to ensure
robust laboratory performance in testing the con-
sortium samples, using masked split duplicates for
5% of samples collected by clinic sites. Intra-
laboratory assay variation was consistently
measured, and performance was excellent and
sustained. Thus, the quality control procedures
have been validated within the limits of the assay.
Even with the different procedures used by the
laboratories, each laboratory performed adequately.
The opportunity to compare results among the
laboratories strengthened efforts to improve the
characteristics of the assays by the thorough and
critical comparison of results. However, the desir-
able outcome of reporting identical, quantitative
results has been approached, but not achieved in
T1DGC. Nevertheless, lessons from the T1DGC
emphasize that interactive collegiality and a will-
ingness among the laboratories to cooperate per-
mits maximal harmonization within the
limitations of each assay. In our case, the laborato-
ries interacted in a continuous, constructive
manner to improve the performances of the
assays in each laboratory. Finally, the T1DGC
leadership and its sponsors continue to recognize
the large amount of effort needed to direct these
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